Skip to content
NERVE.NEWS
TodayStoriesWinners & LosersForecasts
Auto
Set the atmosphere

Scenery follows the section you’re exploring.

Subscribe

Explore Nerve

Desks & tools

The briefingStory hubsForecastsPrimersLiveblogWinners & LosersSearchSaved storiesDataWires

Categories

All categories →PoliticsEconomyForeign AffairsDefense & SecurityImmigration & BorderMedia & TechCulture & SocietyLaw & JusticeEducationDaily RoundupNewsroom
Subscribe to Nerve
Higher contrast, reduced visual effects, and simplified popups. Your choice is saved for this browser.
TodayBriefingSaved
Back to the briefingBriefingNERVE.NEWS
Loading the next story…

The Nerve Briefing

Power, culture, technology, and the world taking shape — when we publish. Subscribe →

NERVE.NEWS

A clear view of a changing world. Reporting and ideas with an American perspective.

Coverage

  • Economy
  • Foreign Affairs
  • Politics
  • Media & Tech
  • Culture & Society
  • Opinion
  • All sections
  • Wires
  • Forecasts

Resources

  • Primers
  • Policy Papers
  • Newsletter
  • RSS — All articles
  • RSS — Wires
  • Data
  • The briefing

Publication

  • Subscribe
  • Winners & Losers
  • Editorial Policy
  • About
© 2026 Nerve News. All rights reserved.
EthicsPrivacyAbout
Home/Wires
WireJuly 30, 2026 at 11:00 PM

Senate Committee Advances Dr. Erica Schwartz for CDC Director

2 min left
0%

Reading controls

Reading Progress0%
Time remaining2 min
Total reading time2 min
Focus modeDims surrounding paragraphs

Editorial note

Comments

Previous

OpenAI Permanently Deactivates Prototype Model After Internal Breach, Raising Questions on Development Pace

Next

Proxy War Widens: U.S.-Iran Talks Continue Through Pakistan as Conflict Reaches Egypt

The Senate Health, Education, Labor, and Pensions Committee advanced the nomination of Dr. Erica Schwartz to become the next director of the Centers for Disease Control and Prevention on Thursday. The vote clears the way for a full Senate confirmation, placing Schwartz at the helm of the sprawling Atlanta-based agency with its $9 billion annual budget.

Schwartz, a retired Coast Guard rear admiral and physician, previously served as the Department of Health and Human Services' deputy surgeon general. Her confirmation process has drawn attention from corporate health interests. Pharmaceutical manufacturers, a significant lobbying presence in Washington contributing over $370 million in 2023 alone, have closely monitored the leadership change at an agency that steers vaccine policy and public health procurement.

National Focus Over Global Entanglements

Supporters within the committee pointed to Schwartz's military background as suited for an agency that has faced scrutiny over its international entanglements and bureaucratic bloat. The CDC employs over 13,000 people and operates in more than 60 countries. Critics argue this global footprint diverts focus from domestic health threats facing American workers and communities, from the opioid crisis in the industrial Midwest to chronic disease epidemics straining the domestic labor force.

The role of foreign influence in public health policy remains a concern. The CDC's extensive collaboration with globalist health bodies, including the World Health Organization from which the prior administration initiated withdrawal, requires an overhaul to prioritize American health sovereignty. Schwartz's confirmation would place her in charge of an agency that has seen its independence and public trust erode amid shifting and often contradictory health guidance.

No timeline was immediately set for the full Senate vote. If confirmed, Schwartz will become the 22nd director of the CDC, stepping into an agency where morale has cratered and a mandate exists to refocus efforts squarely on the health of American citizens.